Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$24.30
▼ $0.20 (-0.8%)
Market data updated: 09/19 10:32 PM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$3.82B
Day Range
$23.75 - $24.48
52-Week Range
$18.01 - $36.80
Beta
—
Next Earnings
28.10.2026
Support
$20.68
Resistance
$24.96
OPCH is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-14.5% (1Y)
Strengths: 13/32 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Operating margin stability
Operating margin is stable or improving over time
Quality
Biggest negative driver
DCF Fair Value
Estimated fair value: $20.64 vs. price $24.30 (-15.1%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
59
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
1d ago · $24.50
Evidence: FOMO score jumped from 16 to 43 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
45
Quality
58
Value
38
Momentum
80
Risk
48
Sentiment
80
Fundamental
51
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **Option Care Health, Inc.** has centered on its **Q2 earnings performance** and **investor sentiment**, with analysts assessing its stock valuation amid a **32% decline over three years**. The company, a leading provider of home and alternate-site infusion services, is being benchmarked against peers in the senior health sector. Additionally, its upcoming participation in major investor conferences—including presentations by CEO John Rademacher and CFO Meenal Sethna—suggests a focus on strategic growth and market positioning. Valuation debates persist, with mixed signals from cash flow and earnings-based models.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Option Care Health, Inc.. News trend score: 80. Reason: 9 of the last 20 articles are positive, versus 4 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
32
🎯 Conviction (vs. Emotion)
41
Psychology
46
Fundamentals
51
Technical
80
Valuation
38
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
+11%
Market Narrative
63
Fundamental Reality
41
Narrative Gap
+22
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior for OPCH suggests a **narrative-reality gap** (57 vs. 41) where optimism (euphoria, overconfidence) slightly outweighs relative underperformance. Herding is dominant due to underperformance relative to peers, while muted FOMO and stable volatility prevent panic or aggressive chasing. The key question is whether the 15% DCF premium reflects justified optimism or overconfidence in a weakening sector. Low volatility and neutral RSI imply no immediate panic, but the gap hints at potential mispricing if fundamentals diverge from current sentiment.
Updated: 09/09/2026, 07:02 AM
What could change this?
👥 What the crowd believes
"Option Care Health stock has had a difficult few years, yet the current valuation checks do not all point in the same direction. The intrinsic value estimate using a Discounted Cash Flow model suggests the shares trade at a premium to that model, while market-based multiples look more supportive."
"Future profitability and cash flow from Option Care Health..."
"Option Care Health, Inc. (‘Option Care Health’) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services"
🧠 Market Brain events driving this
📈 9D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 71/100
🔴 Weakest match
Benjamin Graham — 22/100
🗣️ Why do they disagree?
This stock sparks a sharp divide among methodologies, with scores ranging from a cautious 70—where Charles Mackay sees no obvious crowd mania—to a resounding 15, where Samuel Armstrong Nelson flags it as overbought. The middle-ground thinkers like Burton Malkiel and John Bogle, or Howard Marks, acknowledge potential but lack strong conviction, suggesting the stock’s case for beating an index or justifying high expectations is weak. Meanwhile, Fisher, Lynch, and Graham’s strict frameworks dismiss it outright, citing insufficient quality, growth, or valuation discipline, while Schwager’s quantitative rigor and Nelson’s cyclical analysis both reject it as a clear opportunity. Only Mackay’s broader market psychology lens offers any optimism, contrasting sharply with the more technical or fundamental skeptics.
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 71
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 61
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 57
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 52
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 48
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 44
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 41
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 35
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 35
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🔴 34
Liquidity position Bagehot would flag as a real risk
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 34
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 27
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 27
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 25
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 24
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 22
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (9 bullish · 1 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
19.3%
Operating Margin
6.0%
Net Margin
3.7%
EBITDA Margin
7.2%
ROE
15.7%
ROA
6.0%
ROIC
—
EPS
$1.28
Cash
$232.62M
Total Debt
$1.16B
Current Ratio
1.53
Debt/Equity
0.88
How is Fair Value calculated? →
Current Price
$24.30
Estimated Fair Value (DCF)
$20.64
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-15.1%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
12.8%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 12.8% | $244.84M | $224.62M |
| 2 | 10.2% | $269.80M | $227.08M |
| 3 | 7.6% | $290.38M | $224.22M |
| 4 | 5.1% | $305.08M | $216.13M |
| 5 | 2.5% | $312.71M | $203.24M |
Base FCF (last actual year)
$217.14M
Terminal Value
$4.93B
Present Value of Terminal Value
$3.20B
Enterprise Value
$4.30B
Net Debt
$928.21M
Equity Value
$3.37B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$8.12
Tangible Book Value per Share (Tangible NAV)
-$3.61
Sentiment based on basic keywords (not AI) — 9 positive, 7 neutral, 4 negative out of the last 20 articles.
Yahoo · 16.9.2026
SeekingAlpha · 15.9.2026
Yahoo · 11.9.2026
Zacks · 11.9.2026
StockStory · 10.9.2026
Yahoo · 10.9.2026
Yahoo · 7.9.2026
Zacks · 7.9.2026
Yahoo · 4.9.2026
Zacks · 4.9.2026
StockStory · 3.9.2026
Yahoo · 3.9.2026
StockStory · 2.9.2026
GlobeNewswire · 2.9.2026
Yahoo · 2.9.2026
Yahoo · 1.9.2026
Simply Wall St. · 1.9.2026
Yahoo · 31.8.2026
Zacks · 31.8.2026
Yahoo · 28.8.2026
Option Care Health, Inc. (OPCH) currently has a StockIQ AI score of 59/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
OPCH currently scores 59/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, OPCH's estimated fair value is $20.64, which is 15.1% below the current price of $24.30. This is one valuation model among several signals in the fair-value category, not a price target.
OPCH's technical score is 80/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Operating margin is stable or improving over time; Current ratio: 1.53; Price is above the 50-day average.
Based on the real signals StockIQ computed: Estimated fair value: $20.64 vs. price $24.30 (-15.1%); Calmar: -0.23 (3y annualized return -10.7% / max drawdown 46.7%); Free cash flow growth: -24.5%.
StockIQ has no recorded dividend payment history for OPCH.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Bhatia Prateek | Grant/Award from Employer | 6.7.2026 | 23,409 | +23,409 | — |
| Bhatia Prateek | Grant/Award from Employer | 6.7.2026 | 16,386 | +16,386 | — |
| Bhatia Prateek | Grant/Award from Employer | 6.7.2026 | 16,386 | +16,386 | — |
| Bhatia Prateek | Grant/Award from Employer | 6.7.2026 | 39,795 | +23,409 | — |
| KRAEMER HARRY M JANSEN JR | Grant/Award from Employer | 20.5.2026 | 8,997 | +8,997 | — |
| Deckmann Natasha | Grant/Award from Employer | 20.5.2026 | 844 | +844 | $22.23 |
| SULLIVAN TIMOTHY P | Grant/Award from Employer | 20.5.2026 | 4,836 | +4,836 | $22.23 |
| Pate R Carter | Grant/Award from Employer | 20.5.2026 | 8,997 | +8,997 | — |
| Bierbower Elizabeth D | Grant/Award from Employer | 20.5.2026 | 8,997 | +8,997 | — |
| KRAEMER HARRY M JANSEN JR | Grant/Award from Employer | 20.5.2026 | 12,079 | +12,079 | $22.23 |
| Wright Norman L. | Grant/Award from Employer | 20.5.2026 | 8,997 | +8,997 | — |
| Bodem Barbara W. | Grant/Award from Employer | 20.5.2026 | 8,997 | +8,997 | — |
| BRANDT ERIC | Grant/Award from Employer | 20.5.2026 | 8,997 | +8,997 | — |
| Deckmann Natasha | Grant/Award from Employer | 20.5.2026 | 8,997 | +8,997 | — |
| BRANDT ERIC | Grant/Award from Employer | 20.5.2026 | 2,643 | +2,643 | $22.23 |
| SULLIVAN TIMOTHY P | Grant/Award from Employer | 20.5.2026 | 8,997 | +8,997 | — |
| BRANDT ERIC | Grant/Award from Employer | 20.5.2026 | 19,356 | +8,997 | — |
| BRANDT ERIC | Grant/Award from Employer | 20.5.2026 | 21,999 | +2,643 | $22.23 |
| Wright Norman L. | Grant/Award from Employer | 20.5.2026 | 24,498 | +8,997 | — |
| Bodem Barbara W. | Grant/Award from Employer | 20.5.2026 | 21,087 | +8,997 | — |
| SULLIVAN TIMOTHY P | Grant/Award from Employer | 20.5.2026 | 82,380 | +8,997 | — |
| SULLIVAN TIMOTHY P | Grant/Award from Employer | 20.5.2026 | 87,216 | +4,836 | $22.23 |
| Pate R Carter | Grant/Award from Employer | 20.5.2026 | 20,620 | +8,997 | — |
| KRAEMER HARRY M JANSEN JR | Grant/Award from Employer | 20.5.2026 | 458,997 | +8,997 | — |
| KRAEMER HARRY M JANSEN JR | Grant/Award from Employer | 20.5.2026 | 471,076 | +12,079 | $22.23 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
12,666,901 shares short as of 2026-08-31 · vs. 13,020,353 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
61.3% of trading volume this week was short selling, vs. 60.5% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology